ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
Predictors and outcomes of healthcare-associated infections in COVID-19 patients.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Candidemia Following Severe COVID-19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta-Analysis.Mycoses · 2024Pooled it
- Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.Mycopathologia · 2021Pooled it
- Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Derivation and validation of a nomogram for predicting nonventilator hospital-acquired pneumonia among older hospitalized patients.BMC pulmonary medicine · 2022Trial
- Humoral immune response following the third dose of BNT162b2 received by employees at a Slovak cancer healthcare facility.Biomedical reports · 2025Article
- Catheter-associated urinary tract infections in the intensive care unit during and after the COVID- 19 pandemic.BMC infectious diseases · 2025Article
- Comparative Evaluation of Effectiveness of Standard of Care Alone and in Combination With Homoeopathic Treatment in COVID-19-Related Rhino-Orbito-Cerebral Mucormycosis (ROCM): Protocol for a Single Blind, Randomized Controlled Trial.JMIR research protocols · 2025Article
- The impact of COVID-19 pandemic on nosocomial infections in the cardiac care unit of a non-epidemic hospital in China.Frontiers in medicine · 2025Article
- Device associated healthcare associated infection (DA-HAI): a detailed analysis of risk factors and outcomes in a university hospital in Rome, Italy.Infection prevention in practice · 2024Article
- Risk of central line-associated bloodstream infections during COVID-19 pandemic in intensive care patients in a tertiary care centre in Saudi Arabia.Epidemiology and infection · 2024Article
- Impact of Povidone Application to Nares in Addition to Chlorhexidine Bath in Critically Ill Patients on Nosocomial Bacteremia and Central Line Blood Stream Infection.Journal of clinical medicine · 2024Article
- Development and validation of machine learning-based models for predicting healthcare-associated bacterial/fungal infections among COVID-19 inpatients: a retrospective cohort study.Antimicrobial resistance and infection control · 2024Article
- Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world.BMC infectious diseases · 2024Article
- Associated Bacterial Coinfections in COVID-19-Positive Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Central Line Associated Bloodstream Infections in Critical Ill Patients during and before the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2023Article
- The emergence of multi-drug-resistant bacteria causing healthcare-associated infections in COVID-19 patients: a retrospective multi-centre study.The Journal of hospital infection · 2023Observational
- The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review.JAC-antimicrobial resistance · 2023Review
- Healthcare-associated infections in Dutch hospitals during the COVID-19 pandemic.Antimicrobial resistance and infection control · 2023Article
- Impact of coronavirus disease 2019 (COVID-19) pandemic in hospital-acquired infections and bacterial resistance at an oncology hospital.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- High level of infection prevention and control in surveyed hospitals in Colombia, 2021.Revista panamericana de salud publica = Pan American journal of public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
introductionHealthcare-associated infections (HAI) after viral illnesses are important sources of morbidity and mortality. This has not been extensively studied in hospitalized COVID-19 patients.
methodsThis study included all COVID-19-positive adult patients (≥18 years) hospitalized between 01 March and 05 August 2020 at the current institution. The Centers for Disease Control and Prevention definition of HAI in the acute care setting was used. The outcomes that were studied were rates and types of infections and in-hospital mortality. Several multivariable logistic regression models were constructed to examine characteristics associated with development of HAI.
resultsFifty-nine (3.7%) of 1565 patients developed 140 separate HAIs from 73 different organisms: 23 were Gram-positive, 39 were Gram-negative and 11 were fungal. Patients who developed HAI did not have higher odds of death (OR 0.85, 95% CI 0.40-1.81, p = 0.69). HAIs were associated with the use of tocilizumab (OR 5.04, 95% CI 2.4-10.6, p < 0.001), steroids (OR 3.8, 95% CI 1.4-10, p = 0.007), hydroxychloroquine (OR 3.0, 95% CI 1.0-8.8, p = 0.05), and acute kidney injury requiring hemodialysis (OR 3.7, 95% CI 1.1-12.8, p = 0.04).
conclusionsHAI were common in hospitalized Covid-19 patients. Tocilizumab and steroids were associated with increased risk of HAIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.